UNLABELLED: Whole-body radiation dosimetry of 11C-raclopride was performed in healthy human volunteers. METHODS: Subjects (n = 6) were scanned with PET. Subjects received single-bolus injections of 11C-raclopride (S-(-)-3,5-dichloro-N-[(1-ethyl-2-pyrrolidinyl)]methyl-2-hydroxy-6-methoxybenzamide) (533 +/- 104 MBq) and were scanned for approximately 110 min with a 2-dimensional whole-body protocol. Regions of interest were placed over all visually identifiable organs and time-activity curves were generated. Residence times were computed as the area under the curve of the time-activity curves, normalized to injected activities and standard values of organ volumes. Absorbed doses were computed according to the MIRD schema with MIRDOSE3.1 software. RESULTS: Organs with the highest radiation burden were gallbladder wall, small intestine, liver, and urinary bladder wall. CONCLUSION: On the basis of the estimated absorbed dose, the maximum allowable single study dose under U.S. federal regulations for studies performed under Radiation Drug Research Committee is 1.58 GBq (42.8 mCi). This is still considerably higher than the doses of 11C-raclopride commonly used in research PET (370-555 MBq).
UNLABELLED: Whole-body radiation dosimetry of 11C-raclopride was performed in healthy human volunteers. METHODS: Subjects (n = 6) were scanned with PET. Subjects received single-bolus injections of 11C-raclopride (S-(-)-3,5-dichloro-N-[(1-ethyl-2-pyrrolidinyl)]methyl-2-hydroxy-6-methoxybenzamide) (533 +/- 104 MBq) and were scanned for approximately 110 min with a 2-dimensional whole-body protocol. Regions of interest were placed over all visually identifiable organs and time-activity curves were generated. Residence times were computed as the area under the curve of the time-activity curves, normalized to injected activities and standard values of organ volumes. Absorbed doses were computed according to the MIRD schema with MIRDOSE3.1 software. RESULTS: Organs with the highest radiation burden were gallbladder wall, small intestine, liver, and urinary bladder wall. CONCLUSION: On the basis of the estimated absorbed dose, the maximum allowable single study dose under U.S. federal regulations for studies performed under Radiation Drug Research Committee is 1.58 GBq (42.8 mCi). This is still considerably higher than the doses of 11C-raclopride commonly used in research PET (370-555 MBq).
Authors: Vijay Dhawan; William Robeson; David Bjelke; Thomas Chaly; Kristin Graf; Matthew Hellman; Limei Zhuo; Meggan Mackay; David Eidelberg Journal: J Nucl Med Date: 2015-04-30 Impact factor: 10.057
Authors: Robert E Davis; Kimberly E Vanover; Yun Zhou; James R Brašić; Maria Guevara; Blanca Bisuna; Weiguo Ye; Vanessa Raymont; William Willis; Anil Kumar; Lorena Gapasin; D Ronald Goldwater; Sharon Mates; Dean F Wong Journal: Psychopharmacology (Berl) Date: 2015-04-07 Impact factor: 4.530
Authors: Jussi Lehto; Jere R Virta; Vesa Oikonen; Anne Roivainen; Pauliina Luoto; Eveliina Arponen; Semi Helin; Johanna Hietamäki; Aila Holopainen; Marita Kailajärvi; Juha M Peltonen; Juha Rouru; Jukka Sallinen; Kirsi Virtanen; Iina Volanen; Mika Scheinin; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2014-09-09 Impact factor: 9.236
Authors: Christopher J Endres; Jennifer M Coughlin; Kenneth L Gage; Crystal C Watkins; Michael Kassiou; Martin G Pomper Journal: J Nucl Med Date: 2012-01-12 Impact factor: 10.057
Authors: Nicholas Seneca; Mette Skinbjerg; Sami S Zoghbi; Jeih-San Liow; Robert L Gladding; Jinsoo Hong; Pavitra Kannan; Edward Tuan; David R Sibley; Christer Halldin; Victor W Pike; Robert B Innis Journal: Synapse Date: 2008-09 Impact factor: 2.562
Authors: Astrid A M van der Veldt; N Harry Hendrikse; Egbert F Smit; Martien P J Mooijer; Anneloes Y Rijnders; Winald R Gerritsen; Jacobus J M van der Hoeven; Albert D Windhorst; Adriaan A Lammertsma; Mark Lubberink Journal: Eur J Nucl Med Mol Imaging Date: 2010-05-27 Impact factor: 9.236
Authors: Valerie Treyer; Johannes Streffer; Simon M Ametamey; Andrea Bettio; Peter Bläuenstein; Mark Schmidt; Fabrizio Gasparini; Uta Fischer; Christoph Hock; Alfred Buck Journal: Eur J Nucl Med Mol Imaging Date: 2007-12-11 Impact factor: 9.236